You just read:

Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH)

News provided by

Eiger BioPharmaceuticals, Inc.

12 Dec, 2016, 08:00 ET